Aptadir Therapeutics develops RNA-based medicines that reactivate genes silenced by abnormal DNA methylation for people with hard-to-treat genetic diseases and cancers.

Founders

• Annalisa Di Ruscio, MD, PhD · Founder
  She is an assistant professor in medicine at Beth Israel Deaconess Medical Center of Harvard Medical School, where she discovered DiRs while working in Daniel Tenen's lab.
• Vittorio De Franciscis, PhD · Founder
  He is a research director at the Italian National Research Council and has more than 35 years of expertise in aptamer technology.
• Daniel G. Tenen, MD · Founder
  He is head of the blood program at the Harvard Stem Cell Institute and a professor of medicine at Harvard Medical School.
• Marcin Kortylewski, PhD · Founder
  He is a professor in the department of immuno-oncology at City of Hope Research and an expert in oligonucleotide therapeutics.
• Giovanni Amabile, PhD · Founder and CEO; at launch, Executive Chairman and acting CEO
  Before Aptadir, he was CEO of Enthera and, before that, CSO at ADIENNE Pharma.

Total raised

$46.6M · as its sources put it, more than the rounds on record